Ryan Haumschild, PharmD, MS, MBA

Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across […]

Video content above is prompted by the following: To set the stage, what are some of the psychological and emotional aspects of treatment decision-making with patients entering the third-line stage of metastatic colorectal cancer? What are your recommendations for involving

Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer. Source link Ryan Haumschild, PharmD, MS, MBA

Let’s discuss the extensive-stage setting first. Beyond chemotherapy, immunotherapies have also been investigated in small cell lung cancer (SCLC). What are the main differences between these 2 classes of medication, and why was it necessary to study these in SCLC?

What are the goals of therapy for patients with lupus nephritis (LN)? What does urgency to treat mean in LN? What are the consequences of untreated LN or renal flares? Objective: Examine strategies for early diagnosis/screening, updated treatment guidelines, and

What are the updated treatment recommendations for lupus nephritis (LN) in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines, and how do they differ from previous guidelines? How do clinical guidelines and recommendations from

Tarlatamab was given accelerated approval in May 2024 for extensive-stage small cell lung cancer (SCLC). How does this therapy work, and what was the important data the led to its approval? What are the main adverse events to watch for,

Video content above is prompted by the following: What has been your experience with the impact of these third-line therapy options (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on a patient’s quality of life? What insights can you share related to patient

Video content above is prompted by the following: How do the toxicity profiles differ with FTD/TPI plus bevacizumab, as compared with regorafenib or fruquintinib, and how might these different toxicity profiles be leveraged when making treatment selections? What are some

Opinion Video September 27, 2024 Panelists discuss the significant clinical and economic burdens of lupus nephritis, including the increased risk of kidney failure and death, and provide current statistics on the prevalence and incidence of lupus nephritis in various populations.